Kisho

Swedish Orphan Biovitrum AB (publ) — Rare Disease Pipeline | Kisho | Kisho

Swedish Orphan Biovitrum AB (publ)

Other

A biopharmaceutical company focused on developing treatments for rare diseases, with six FDA-approved drugs and five orphan drug designations across 18 conditions, including various genetic disorders and psoriasis.

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
ALG9-congenital disorder of glycosylation	Kineret	Orphan Designation	-
CINCA syndrome	Kineret	Orphan Designation	-
Muckle-Wells syndrome	Kineret	Orphan Designation	-
alkaptonuria	nitisinone	Orphan Designation	-
cryopyrin-associated periodic syndrome	Kineret	Orphan Designation	-
deficiency of adenosine deaminase 2	Kineret	Orphan Designation	-
deficiency of coenzyme q cytochrome c reductase	Kineret	Orphan Designation	-
familial cold autoinflammatory syndrome 1	Kineret	Orphan Designation	-
hereditary hemochromatosis	Orfadin	Orphan Designation	-
hereditary hemorrhagic telangiectasia	Orfadin	Orphan Designation	-
hereditary multiple osteochondromas	Orfadin	Orphan Designation	-
hereditary spastic paraplegia	Orfadin	Orphan Designation	-
immunodeficiency 67	Kineret	Orphan Designation	-
neonatal-onset encephalopathy with rigidity and seizures	Kineret	Orphan Designation	-
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2	Kineret	Orphan Designation	-
psoriasis 14, pustular	Kineret	Orphan Designation	-
sterile multifocal osteomyelitis with periostitis and pustulosis	Kineret	Orphan Designation	-
tyrosinemia type I	Orfadin	Orphan Designation	-

← Back to Companies